Role of maspin in cancer
Open Access
- 7 March 2013
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 2 (1), 8
- https://doi.org/10.1186/2001-1326-2-8
Abstract
Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily. Its expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic, gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activities in different cell types. However, maspin expression seems to be correlated with better prognosis in prostate, bladder, lung, gastric, colorectal, head and neck, thyroid and melanoma cancer. In breast and ovarian cancer maspin significance is associated with its subcellular localization: nucleus maspin expression correlates with a good prognosis, whilst in pancreatic cancer it predicts a poor prognosis. Since tumor metastasis requires the detachment and invasion of tumor cells through the basement membrane and stroma, a selectively increased adhesion by the presence of maspin may contribute to the inhibition of tumor metastasis. Furthermore the different position of maspin inside the cell or its epigenetic modifications may explain the different behavior of the expression of maspin between tumors. The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age, comorbidities, blood examinations in order to select the best therapy to be carried out. Focusing on the malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the expression of maspin, to identify natural substances that can determine the activation and the expression of maspin or possible “molecules binds” to introduce maspin in cancer cell and gene therapy capable of up-regulating the maspin in an attempt to reduce primarily the risk of metastasis. Further studies in these directions are necessary to better define the therapeutic implication of maspin.Keywords
This publication has 137 references indexed in Scilit:
- Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotypeProceedings of the National Academy of Sciences of the United States of America, 2010
- G-helix of Maspin Mediates Effects on Cell Migration and AdhesionOnline Journal of Public Health Informatics, 2010
- Maspin (SERPINB5) Is an Obligate Intracellular SerpinOnline Journal of Public Health Informatics, 2010
- Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survivalHistopathology, 2009
- Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKTOncogene, 2008
- Elucidating the Function of Secreted Maspin: Inhibiting Cathepsin D–Mediated Matrix DegradationCancer Research, 2007
- Maspin: The New FrontierClinical Cancer Research, 2006
- Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancerJournal of Clinical Pathology, 2006
- Simultaneous evaluation of maspin and CXCR4 in patients with breast cancerJournal of Clinical Pathology, 2006
- Mutant p53 and aberrant cytosine methylation cooperate to silence gene expressionOncogene, 2003